These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 27611088)

  • 21. Assessing the epidemiological impact on cervical cancer of switching from 4-valent to 9-valent HPV vaccine within a gender-neutral vaccination programme in Switzerland.
    Kind AB; Pavelyev A; Kothari S; El Mouaddin N; Schmidt A; Morais E; Guggisberg P; Lienert F
    BMC Public Health; 2020 May; 20(1):671. PubMed ID: 32398057
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The effects of the national HPV vaccination programme in England, UK, on cervical cancer and grade 3 cervical intraepithelial neoplasia incidence: a register-based observational study.
    Falcaro M; Castañon A; Ndlela B; Checchi M; Soldan K; Lopez-Bernal J; Elliss-Brookes L; Sasieni P
    Lancet; 2021 Dec; 398(10316):2084-2092. PubMed ID: 34741816
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Active Surveillance of Adverse Events Following Human Papillomavirus Vaccination: Feasibility Pilot Study Based on the Regional Health Care Information Platform in the City of Ningbo, China.
    Liu Z; Zhang L; Yang Y; Meng R; Fang T; Dong Y; Li N; Xu G; Zhan S
    J Med Internet Res; 2020 Jun; 22(6):e17446. PubMed ID: 32234696
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Well-being of women referred due to suspected side effects after human papilloma virus vaccination.
    Kjaer J; Jensen TS; Rolving N; Sørensen VN; Blaakaer J; Hammer A
    Dan Med J; 2020 Jun; 67(6):. PubMed ID: 32741432
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Human Papillomavirus Vaccination and Cervical Cytology Outcomes Among Urban Low-Income Minority Females.
    Hofstetter AM; Ompad DC; Stockwell MS; Rosenthal SL; Soren K
    JAMA Pediatr; 2016 May; 170(5):445-52. PubMed ID: 26974250
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Knowledge and willingness of parents towards child girl HPV vaccination in Debre Tabor Town, Ethiopia: a community-based cross-sectional study.
    Mihretie GN; Liyeh TM; Ayele AD; Belay HG; Yimer TS; Miskr AD
    Reprod Health; 2022 Jun; 19(1):136. PubMed ID: 35689288
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety profile of human papilloma virus vaccines: an analysis of the US Vaccine Adverse Event Reporting System from 2007 to 2017.
    Bonaldo G; Vaccheri A; D'Annibali O; Motola D
    Br J Clin Pharmacol; 2019 Mar; 85(3):634-643. PubMed ID: 30569481
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Suboptimal uptake of human papillomavirus (HPV) vaccine in survivors of childhood and adolescent and young adult (AYA) cancer.
    Castellino SM; Allen KE; Pleasant K; Keyes G; Poehling KA; Tooze JA
    J Cancer Surviv; 2019 Oct; 13(5):730-738. PubMed ID: 31342304
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adverse events following HPV vaccination, Alberta 2006-2014.
    Liu XC; Bell CA; Simmonds KA; Svenson LW; Russell ML
    Vaccine; 2016 Apr; 34(15):1800-5. PubMed ID: 26921782
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Do parental education and income matter? A nationwide register-based study on HPV vaccine uptake in the school-based immunisation programme in Norway.
    Feiring B; Laake I; Molden T; Cappelen I; Håberg SE; Magnus P; Steingrímsdóttir ÓA; Strand BH; Stålcrantz J; Trogstad L
    BMJ Open; 2015 May; 5(5):e006422. PubMed ID: 25991445
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Opportunistic HPV vaccination at age 16-23 and cervical screening attendance in Sweden: a national register-based cohort study.
    Kreusch T; Wang J; Sparén P; Sundström K
    BMJ Open; 2018 Oct; 8(10):e024477. PubMed ID: 30282687
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The projected timeframe until cervical cancer elimination in Australia: a modelling study.
    Hall MT; Simms KT; Lew JB; Smith MA; Brotherton JM; Saville M; Frazer IH; Canfell K
    Lancet Public Health; 2019 Jan; 4(1):e19-e27. PubMed ID: 30291040
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Post-marketing surveillance study of the safety of the HPV-16/18 vaccine in Korea (2017-2021).
    Eun BW; Bahar E; Xavier S; Kim H; Borys D
    Hum Vaccin Immunother; 2023 Dec; 19(1):2184756. PubMed ID: 36896702
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Primary care providers human papillomavirus vaccine recommendations for the medically underserved: a pilot study in U.S. Federally Qualified Health Centers.
    Roland KB; Benard VB; Greek A; Hawkins NA; Saraiya M
    Vaccine; 2014 Sep; 32(42):5432-5. PubMed ID: 25131744
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Association between human papillomavirus vaccination and serious adverse events in South Korean adolescent girls: nationwide cohort study.
    Yoon D; Lee JH; Lee H; Shin JY
    BMJ; 2021 Jan; 372():m4931. PubMed ID: 33514507
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ten-year follow-up of human papillomavirus vaccine efficacy against the most stringent cervical neoplasia end-point-registry-based follow-up of
    Lehtinen M; Lagheden C; Luostarinen T; Eriksson T; Apter D; Harjula K; Kuortti M; Natunen K; Palmroth J; Petäjä T; Pukkala E; Siitari-Mattila M; Struyf F; Nieminen P; Paavonen J; Dubin G; Dillner J
    BMJ Open; 2017 Aug; 7(8):e015867. PubMed ID: 28821519
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The impact of over ten years of HPV vaccination in England: Surveillance of type-specific HPV in young sexually active females.
    Checchi M; Mesher D; Panwar K; Anderson A; Beddows S; Soldan K
    Vaccine; 2023 Oct; 41(45):6734-6744. PubMed ID: 37821315
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy, immunogenicity, and safety of a quadrivalent HPV vaccine in men: results of an open-label, long-term extension of a randomised, placebo-controlled, phase 3 trial.
    Goldstone SE; Giuliano AR; Palefsky JM; Lazcano-Ponce E; Penny ME; Cabello RE; Moreira ED; Baraldi E; Jessen H; Ferenczy A; Kurman R; Ronnett BM; Stoler MH; Bautista O; Das R; Group T; Luxembourg A; Zhou HJ; Saah A
    Lancet Infect Dis; 2022 Mar; 22(3):413-425. PubMed ID: 34780705
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Reports of Postural Orthostatic Tachycardia Syndrome After Human Papillomavirus Vaccination in the Vaccine Adverse Event Reporting System.
    Arana J; Mba-Jonas A; Jankosky C; Lewis P; Moro PL; Shimabukuro TT; Cano M
    J Adolesc Health; 2017 Nov; 61(5):577-582. PubMed ID: 29061232
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effectiveness of the quadrivalent human papillomavirus vaccine against cervical dysplasia in Manitoba, Canada.
    Mahmud SM; Kliewer EV; Lambert P; Bozat-Emre S; Demers AA
    J Clin Oncol; 2014 Feb; 32(5):438-43. PubMed ID: 24395857
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.